Association of Cytochrome P450 with Cancer Induced by Betel Quid (BQ): A Review

Adhikari, Achyut; De, Madhusnata

doi:10.21767/2393-8862.100031

Cited by 5 publications

(3 citation statements)

References 46 publications

(53 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As a superfamily of enzymes related to phase I drug metabolism, Cytochrome P450 (CYP) was involved in multiple biological processes, such as maintaining calcium homeostasis, fatty acid metabolism, and steroid and cholesterol biosynthesis [33]. CYP4B1 (cytochrome P450 family 4 subfamily B member 1) is an extrahepatic form of cytochrome P450 predominantly and responsible for the bioactivation of multiple protoxins with tissuespecific toxicological effects [34].…”

Section: Discussionmentioning

confidence: 99%

Prognostic Ability of Enhancer RNAs in Metastasis of Non-Small Cell Lung Cancer

Liu

Wang²,

Zhang³

et al. 2022

Molecules

View full text Add to dashboard Cite

(1) Background: Non-small cell lung cancer (NSCLC) is the most common lung cancer. Enhancer RNA (eRNA) has potential utility in the diagnosis, prognosis and treatment of cancer, but the role of eRNAs in NSCLC metastasis is not clear; (2) Methods: Differentially expressed transcription factors (DETFs), enhancer RNAs (DEEs), and target genes (DETGs) between primary NSCLC and metastatic NSCLC were identified. Prognostic DEEs (PDEEs) were screened by Cox regression analyses and a predicting model for metastatic NSCLC was constructed. We identified DEE interactions with DETFs, DETGs, reverse phase protein arrays (RPPA) protein chips, immunocytes, and pathways to construct a regulation network using Pearson correlation. Finally, the mechanisms and clinical significance were explained using multi-dimensional validation unambiguously; (3) Results: A total of 255 DEEs were identified, and 24 PDEEs were selected into the multivariate Cox regression model (AUC = 0.699). Additionally, the NSCLC metastasis-specific regulation network was constructed, and six key PDEEs were defined (ANXA8L1, CASTOR2, CYP4B1, GTF2H2C, PSMF1 and TNS4); (4) Conclusions: This study focused on the exploration of the prognostic value of eRNAs in the metastasis of NSCLC. Finally, six eRNAs were identified as potential markers for the prediction of metastasis of NSCLC.

show abstract

Section: Discussionmentioning

confidence: 99%

Prognostic Ability of Enhancer RNAs in Metastasis of Non-Small Cell Lung Cancer

Liu

Wang²,

Zhang³

et al. 2022

Molecules

View full text Add to dashboard Cite

show abstract

“…Cytochrome P450 (CYP) is a superfamily of enzymes and a typical phase I drug metabolism enzyme, which is located in the inner membrane of mitochondria and the endoplasmic reticulum membrane of eukaryotic cells. [8,14]. CYP4B1 is a member of the CYP4B subfamily, and the current researches on CYP4B1 gene mainly focus on its function analysis.…”

Section: Discussionmentioning

confidence: 99%

Case-control study on CYP4B1 gene polymorphism and susceptibility to gastric cancer in the chinese Han population

Chen

Cheng

et al. 2022

BMC Med Genomics

View full text Add to dashboard Cite

Background: In China, gastric cancer (GC) is one of the most common malignant tumors. This study aimed to explore the relationship of rs2297810, rs4646491 and rs2297809 polymorphisms of CYP4B1 with susceptibility to GC in the Chinese Han population. Methods: A case-control study including 707 GC cases and 707 normal controls was conducted. Three single nucleotide polymorphisms (SNPs) were genotyped by Agena MassARRAY system. Logistic regression analysis was utilized to assess the effects of SNPs on GC risk. Furthermore, multifactor dimensionality reduction (MDR) approach was used to analyze the SNP-SNP interactions. Results: No significant relationships were found between rs2297810 and rs2297809 and GC risk under all genetic models. For rs4646491, people with TC genotype had a 1.40-fold higher risk of GC than those with CC genotype (OR = 1.40; 95% CI = 1.13–1.74; p = 0.002), and people with TT-TC genotype had a 1.30-fold higher risk of GC than those with CC genotype (OR = 1.30; 95% CI = 1.06–1.61; p = 0.014). Stratification results showed that GC risk in people carrying TC genotype was higher than that in people with CC genotype, males (OR = 1.36; 95% CI = 1.06–1.75; p = 0.015), non-smokers (OR = 1.52; 95% CI = 1.11–2.07; p = 0.009) and non-drinkers (OR = 1.50; 95% CI = 1.10–2.04; p = 0.010). Additionally, the study also revealed that GC risk in people carrying TT-TC genotype was higher than that in people with CC genotype, males (OR = 1.29; 95% CI = 1.01–1.64; p = 0.040), non-smokers (OR = 1.40; 95% CI = 1.04–1.89; p = 0.027) and non-drinkers (OR = 1.39; 95% CI = 1.03–1.87; p = 0.030). Conclusion: This study firstly found that CYP4B1-rs4646491 was significantly correlated with GC risk, and it might be a risk factor for GC.

show abstract

“…Cytochrome P450 (CYP), a superfamily of cysteinato-heme monooxygenases, is an essential element of in this system. It serves as the most important phase I drug metabolism enzyme system, undertaking oxidative reactions in the body [ 7 ]. Furthermore, it is widely involved in the metabolic processes of exogenous drugs, environmental poisons, carcinogens, and endogenous hormones, thus playing a pivotal role in regulating the interaction between the organism and the external environment, as well as in maintaining the homeostasis in vivo .…”

Section: Introductionmentioning

confidence: 99%

CYP4B1 is a prognostic biomarker and potential therapeutic target in lung adenocarcinoma

et al. 2021

View full text Add to dashboard Cite

CYP4B1 belongs to the mammalian CYP4 enzyme family and is predominantly expressed in the lungs of humans. It is responsible for the oxidative metabolism of a wide range of endogenous compounds and xenobiotics. In this study, using data from The Cancer Genome Atlas (TCGA) project and the Gene Expression Omnibus (GEO) database, a secondary analysis was performed to explore the expression profile of CYP4B1, as well as its prognostic value in patients with lung adenocarcinoma (LUAD). Based on the obtained results, a significantly decreased CYP4B1 expression was discovered in patients with LUAD when compared with their normal counterparts (p<0.05), and was linked to age younger than 65 years (p = 0.0041), history of pharmaceutical (p = 0.0127) and radiation (p = 0.0340) therapy, mutations in KRAS/EGFR/ALK (p = 0.0239), and living status of dead (p = 0.0026). Survival analysis indicated that the low CYP4B1 expression was an independent prognostic indicator of shorter survival in terms of overall survival (OS) and recurrence-free survival (RFS) in patients with LUAD. The copy number alterations (CNAs) and sites of cg23440155 and cg23414387 hypermethylation might contribute to the decreased CYP4B1 expression. Gene set enrichment analysis (GSEA) suggested that CYP4B1 might act as an oncogene in LUAD by preventing biological metabolism pathways of exogenous and endogenous compounds and enhancing DNA replication and cell cycle activities. In conclusion, CYP4B1 expression may serve as a valuable independent prognostic biomarker and a potential therapeutic target in patients with LUAD.

show abstract

Association of Cytochrome P450 with Cancer Induced by Betel Quid (BQ): A Review

Cited by 5 publications

References 46 publications

Prognostic Ability of Enhancer RNAs in Metastasis of Non-Small Cell Lung Cancer

Prognostic Ability of Enhancer RNAs in Metastasis of Non-Small Cell Lung Cancer

Case-control study on CYP4B1 gene polymorphism and susceptibility to gastric cancer in the chinese Han population

CYP4B1 is a prognostic biomarker and potential therapeutic target in lung adenocarcinoma

Contact Info

Product

Resources

About